Do analysts recommend ACRV or ELYM?

Acrivon Therapeutics presently has a consensus target price of $13.50, suggesting a potential upside of 578.39%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, ACRV or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is ACRV or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% Eliem Therapeutics N/A -47.03% -45.97%

Which has stronger earnings & valuation, CYPH or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M $0.56 5.41 Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is CYPH or ACRV more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -20.76% -19.48% Acrivon Therapeutics N/A -70.14% -61.60%

Is ARTV or ACRV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Acrivon Therapeutics N/A -70.14% -61.60%

Which has stronger earnings & valuation, ACRV or BNTC?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A

Is ACRV or BNTC more profitable?

Benitec Biopharma's return on equity of -28.41% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% Benitec Biopharma N/A -28.41% -27.76%

Acrivon Therapeutics (ACRV) Competitors

$1.99 -0.02 (-1.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.03 +0.04 (+1.91%)

As of 10/2/2026 07:43 PM Eastern

Compare

ACRV vs. EBS, ELYM, CYPH, ARTV, and BNTC

Should you buy Acrivon Therapeutics stock or one of its competitors? Acrivon Therapeutics's main competitors and comparable companies include Emergent Biosolutions (EBS), Eliem Therapeutics (ELYM), Cypherpunk Technologies (CYPH), Artiva Biotherapeutics (ARTV), and Benitec Biopharma (BNTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Acrivon Therapeutics compare to Emergent Biosolutions?

Acrivon Therapeutics (NASDAQ:ACRV) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Acrivon Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market.

Emergent Biosolutions has higher revenue and earnings than Acrivon Therapeutics. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Emergent Biosolutions	$742.90M	0.44	$52.60M	-$3.55	N/A

Acrivon Therapeutics presently has a consensus target price of $13.50, indicating a potential upside of 578.39%. Emergent Biosolutions has a consensus target price of $10.00, indicating a potential upside of 58.10%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Acrivon Therapeutics has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Emergent Biosolutions	-22.95%	16.35%	6.17%

In the previous week, Emergent Biosolutions had 3 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 3 mentions for Emergent Biosolutions and 0 mentions for Acrivon Therapeutics. Emergent Biosolutions' average media sentiment score of 0.46 beat Acrivon Therapeutics' score of -0.67 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Overall Sentiment
Acrivon Therapeutics	Negative
Emergent Biosolutions	Neutral

Summary

Emergent Biosolutions beats Acrivon Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Eliem Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Eliem Therapeutics' return on equity of -47.03% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Eliem Therapeutics	N/A	-47.03%	-45.97%

In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 beat Acrivon Therapeutics' score of -0.67 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Acrivon Therapeutics	Negative
Eliem Therapeutics	Neutral

Acrivon Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Acrivon Therapeutics presently has a consensus target price of $13.50, suggesting a potential upside of 578.39%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Eliem Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Cypherpunk Technologies has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

Cypherpunk Technologies currently has a consensus target price of $4.90, indicating a potential upside of 61.72%. Acrivon Therapeutics has a consensus target price of $13.50, indicating a potential upside of 578.39%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cypherpunk Technologies' return on equity of -20.76% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Cypherpunk Technologies had 6 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 0 mentions for Acrivon Therapeutics. Cypherpunk Technologies' average media sentiment score of 0.46 beat Acrivon Therapeutics' score of -0.67 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Neutral
Acrivon Therapeutics	Negative

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	5.41
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Summary

Cypherpunk Technologies beats Acrivon Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 471.01%. Acrivon Therapeutics has a consensus target price of $13.50, indicating a potential upside of 578.39%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Artiva Biotherapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Acrivon Therapeutics has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,335.67	-$83.86M	-$3.30	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Artiva Biotherapeutics' return on equity of -53.86% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

In the previous week, Artiva Biotherapeutics had 7 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 0 mentions for Acrivon Therapeutics. Artiva Biotherapeutics' average media sentiment score of -0.02 beat Acrivon Therapeutics' score of -0.67 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Artiva Biotherapeutics	Neutral
Acrivon Therapeutics	Negative

Summary

Artiva Biotherapeutics beats Acrivon Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Benitec Biopharma?

Acrivon Therapeutics (NASDAQ:ACRV) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Acrivon Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Benitec Biopharma's return on equity of -28.41% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Benitec Biopharma	N/A	-28.41%	-27.76%

In the previous week, Benitec Biopharma had 7 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Benitec Biopharma and 0 mentions for Acrivon Therapeutics. Benitec Biopharma's average media sentiment score of -0.62 beat Acrivon Therapeutics' score of -0.67 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Acrivon Therapeutics	Negative
Benitec Biopharma	Negative

Benitec Biopharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Acrivon Therapeutics currently has a consensus price target of $13.50, indicating a potential upside of 578.39%. Benitec Biopharma has a consensus price target of $24.00, indicating a potential upside of 167.26%. Given Acrivon Therapeutics' higher probable upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Benitec Biopharma beats Acrivon Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$85.28M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-1.06	13.06	275.66	26.04
Price / Sales	N/A	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.56	16.63	10.93	6.31
Net Income	-$77.90M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-5.24%	-2.99%	-2.00%	-1.66%
1 Month Performance	-6.57%	-10.81%	-6.19%	-4.68%
1 Year Performance	4.19%	19.19%	8.03%	1.57%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	2.6012 of 5 stars	$1.99 -1.0%	$13.50 +578.4%	+4.2%	$85.28M	N/A	N/A	76
EBS Emergent Biosolutions	3.7842 of 5 stars	$6.94 +1.1%	$10.00 +44.2%	-30.6%	$355.56M	$742.90M	N/A	900
ELYM Eliem Therapeutics	N/A	$11.74 +0.7%	N/A	+455.3%	$349.29M	N/A	N/A	9
CYPH Cypherpunk Technologies	3.0063 of 5 stars	$3.23 -2.4%	$4.90 +51.7%	+467.9%	$348.07M	N/A	5.77	40	Analyst Downgrade Gap Up High Trading Volume
ARTV Artiva Biotherapeutics	2.8396 of 5 stars	$7.03 -0.3%	$39.00 +454.8%	+131.5%	$343.70M	$250K	N/A	115	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. EBS, ELYM, CYPH, ARTV, and BNTC

How does Acrivon Therapeutics compare to Emergent Biosolutions?

Summary

How does Acrivon Therapeutics compare to Eliem Therapeutics?

Summary

How does Acrivon Therapeutics compare to Cypherpunk Technologies?

Summary

How does Acrivon Therapeutics compare to Artiva Biotherapeutics?

Summary

How does Acrivon Therapeutics compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. EBS, ELYM, CYPH, ARTV, and BNTC

How does Acrivon Therapeutics compare to Emergent Biosolutions?

Do institutionals and insiders have more ownership in ACRV or EBS?

Which has more risk & volatility, ACRV or EBS?

Which has stronger earnings & valuation, ACRV or EBS?

Do analysts recommend ACRV or EBS?

Is ACRV or EBS more profitable?

Does the media favor ACRV or EBS?

Summary

How does Acrivon Therapeutics compare to Eliem Therapeutics?

Is ACRV or ELYM more profitable?

Does the media refer more to ACRV or ELYM?

Which has more risk and volatility, ACRV or ELYM?

Which has better earnings & valuation, ACRV or ELYM?

Do analysts recommend ACRV or ELYM?

Do insiders & institutionals hold more shares of ACRV or ELYM?

Summary

How does Acrivon Therapeutics compare to Cypherpunk Technologies?

Which has more volatility and risk, CYPH or ACRV?

Do analysts rate CYPH or ACRV?

Is CYPH or ACRV more profitable?

Do institutionals & insiders believe in CYPH or ACRV?

Does the media prefer CYPH or ACRV?

Which has stronger earnings & valuation, CYPH or ACRV?

Summary

How does Acrivon Therapeutics compare to Artiva Biotherapeutics?

Do analysts rate ARTV or ACRV?

Do institutionals and insiders have more ownership in ARTV or ACRV?

Which has more volatility & risk, ARTV or ACRV?

Which has stronger valuation and earnings, ARTV or ACRV?

Is ARTV or ACRV more profitable?

Does the media refer more to ARTV or ACRV?

Summary

How does Acrivon Therapeutics compare to Benitec Biopharma?

Which has more volatility and risk, ACRV or BNTC?

Is ACRV or BNTC more profitable?

Does the media prefer ACRV or BNTC?

Which has stronger earnings & valuation, ACRV or BNTC?

Do institutionals & insiders believe in ACRV or BNTC?

Do analysts recommend ACRV or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools